Teva Pharma

Armodafinil (NUVIGIL) is an oral small-molecule wakefulness-promoting agent being developed by Teva Pharma GmbH for schizophrenia. The program, identified by internal code C10953/2034/SZ/MN, completed Phase 2 clinical development with a final milestone recorded on 19 July 2013. Armodafinil is the active R-enantiomer of modafinil and has been approved in multiple jurisdictions for other indications, including the United States (NDA021875) and Australia (first listed 1 November 2016). The schizophrenia program represents an investigational use of an established pharmacological entity. Two clinical trials (NCT00487942 and NCT00772005) supported the Phase 2 evaluation. The mechanism of action and specific target for the schizophrenia indication have not been disclosed. Following completion of Phase 2 in 2013, no subsequent development milestones or regulatory filings have been reported, indicating the program may be inactive or in extended evaluation. The competitive landscape for schizophrenia includes numerous approved antipsychotics and adjunctive therapies, positioning armodafinil as a potential add-on or alternative agent rather than a primary treatment.

Schizophrenia affects approximately 1% of the global population and remains a significant unmet medical need despite the availability of multiple antipsychotic agents. Negative symptoms, cognitive dysfunction, and treatment-resistant cases continue to challenge clinical management. Armodafinil's potential role in schizophrenia may address cognitive or negative symptom domains, as wakefulness-promoting agents have been explored as adjunctive therapies in psychiatric conditions. The drug's established safety profile in other indications (narcolepsy, obstructive sleep apnea, shift work sleep disorder) could facilitate development and regulatory acceptance if efficacy is demonstrated.

Commercially, armodafinil is already marketed globally through multiple manufacturers under the NUVIGIL brand and generic formulations, reducing development costs and enabling rapid commercialization if the schizophrenia indication is approved. The competitive landscape includes established antipsychotics (aripiprazole, olanzapine, risperidone, clozapine) and emerging adjunctive therapies (valbenazine, brexpiprazole, cariprazine). A successful schizophrenia indication would represent label expansion for an existing marketed product, potentially capturing market share in the adjunctive or resistant-symptom segments. However, the absence of reported milestones since 2013 suggests commercial or clinical challenges may have halted advancement.

Drug Class: Wakefulness-promoting agent (eugeroic); established small-molecule pharmaceutical.

Modality: Small molecule, oral administration.

Molecular Identity: Armodafinil is the R-enantiomer of modafinil, a racemic mixture. The mechanism of action and specific neurobiological target in schizophrenia have not been disclosed in available sources.

Route of Administration: Oral.

Related Therapies: Modafinil (parent compound), other wakefulness-promoting agents, and adjunctive psychiatric medications.

Regulatory History (Non-Schizophrenia Indications):

• United States: Approved via NDA021875; multiple generic manufacturers hold ANDAs (Aurobindo Pharma, CorePharma, Lupin, Mylan, Natco, Nuvo, Teva, Watson).
• Australia: Approved and listed on ARTG (PBS codes 10912H, 10919Q, 10922W) by Teva Pharma Australia Pty Ltd, effective 1 November 2016.

Patent Status: Not yet disclosed.

United States: Armodafinil is approved via NDA021875 for non-psychiatric indications. Multiple generic manufacturers hold approved ANDAs (ANDA200043, ANDA200152, ANDA200156, ANDA200751, ANDA201514, ANDA202768, ANDA206069). FDA approval status for the schizophrenia indication is not yet disclosed.

Australia: Armodafinil is approved and listed on the ARTG with PBS codes 10912H, 10919Q, 10922W, sponsored by Teva Pharma Australia Pty Ltd, effective 1 November 2016. Approval status for schizophrenia indication in Australia is not yet disclosed.

European Union (EMA): Regulatory status not yet disclosed.

Japan (PMDA): Regulatory status not yet disclosed.

China (NMPA): Regulatory status not yet disclosed.

No IND, BLA, or NDA filings for the schizophrenia indication have been reported. The program remains in completed Phase 2 status with no announced regulatory submissions.

Strategic Implications: Teva's development of armodafinil for schizophrenia represents a repurposing strategy leveraging an established, marketed asset. This approach reduces development risk and cost compared to de novo drug discovery. However, the completion of Phase 2 in July 2013 without subsequent reported milestones (over a decade ago) suggests the program may have encountered efficacy, safety, or commercial challenges that halted advancement.

Competitive Implications: The schizophrenia market is saturated with approved antipsychotics and emerging adjunctive therapies. Armodafinil's differentiation as a wakefulness-promoting agent targeting potential cognitive or negative symptoms is conceptually sound but faces competition from established agents with robust clinical evidence and established market presence. The absence of recent development activity suggests Teva may have deprioritized this indication.

Future Catalysts: Potential catalysts include resumption of clinical development, publication of Phase 2 trial results, regulatory submissions, or strategic partnership announcements. The lack of disclosed milestones since 2013 indicates these catalysts are not imminent.

Expected Milestones: No expected next milestones have been disclosed. If development resumes, Phase 3 initiation, regulatory consultation meetings, or clinical trial publications would represent key catalysts.